Published in J Am Soc Nephrol on April 29, 2010
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Ciliopathies: an expanding disease spectrum. Pediatr Nephrol (2011) 2.95
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
The cell biology of polycystic kidney disease. J Cell Biol (2010) 1.58
Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol (2012) 1.57
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int (2015) 1.50
Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol (2013) 1.46
Evaluation of hepatic cystic lesions. World J Gastroenterol (2013) 1.43
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol (2013) 1.33
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol (2014) 1.23
Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant (2012) 1.20
Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc Natl Acad Sci U S A (2011) 1.18
The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2011) 1.12
Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol (2012) 1.10
Current insights into renal ciliopathies: what can genetics teach us? Pediatr Nephrol (2012) 1.08
Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J Gastroenterol (2013) 1.04
Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol (2014) 1.03
Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology (2013) 1.03
Polycystic kidney disease: pathogenesis and potential therapies. Biochim Biophys Acta (2010) 1.02
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis (2013) 1.01
Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology (2011) 1.00
Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells. Biochim Biophys Acta (2010) 1.00
The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci (2012) 0.99
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology (2012) 0.99
The Cholangiopathies. Mayo Clin Proc (2015) 0.98
TGR5 in the Cholangiociliopathies. Dig Dis (2015) 0.97
Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. Pediatr Nephrol (2012) 0.97
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol (2014) 0.94
Molecular pathways and therapies in autosomal-dominant polycystic kidney disease. Physiology (Bethesda) (2015) 0.93
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle (2012) 0.91
Educational paper: ciliopathies. Eur J Pediatr (2011) 0.90
Urine proteome of autosomal dominant polycystic kidney disease patients. Clin Proteomics (2012) 0.89
Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2012) 0.88
Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol (2014) 0.87
Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol (2012) 0.86
Cilium, centrosome and cell cycle regulation in polycystic kidney disease. Biochim Biophys Acta (2011) 0.85
New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol (2013) 0.85
The role of cilia in the regulation of bile flow. Dig Dis (2011) 0.85
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol (2015) 0.84
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2013) 0.84
ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010. Am J Kidney Dis (2014) 0.84
Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. Am J Physiol Renal Physiol (2012) 0.84
Renal function can improve at any stage of chronic kidney disease. PLoS One (2013) 0.83
Current management of noninfectious hepatic cystic lesions: A review of the literature. World J Hepatol (2013) 0.83
Supervised segmentation of polycystic kidneys: a new application for stereology data. J Digit Imaging (2014) 0.83
Novel treatments of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 0.83
A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant (2014) 0.82
Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clin Proc (2015) 0.82
Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. Trials (2011) 0.82
Current management of autosomal dominant polycystic kidney disease. World J Nephrol (2015) 0.82
Combined liver and kidney transplant in a patient with budd-Chiari syndrome secondary to autosomal dominant polycystic kidney disease associated with polycystic liver disease: report of a case with a 9-year follow-up. Case Rep Gastrointest Med (2014) 0.81
An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr (2014) 0.81
Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2016) 0.81
3D spheroid defects in NPHP knockdown cells are rescued by the somatostatin receptor agonist octreotide. Am J Physiol Renal Physiol (2012) 0.81
ADPKD: Prototype of Cardiorenal Syndrome Type 4. Int J Nephrol (2010) 0.81
Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images. AJR Am J Roentgenol (2016) 0.81
Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study. BMC Nephrol (2014) 0.80
Randomized intervention studies in human polycystic kidney and liver disease. J Am Soc Nephrol (2010) 0.80
Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease. PLoS One (2015) 0.79
HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am J Pathol (2014) 0.78
Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. Clin Exp Nephrol (2014) 0.78
Volume regression of native polycystic kidneys after renal transplantation. Nephrol Dial Transplant (2015) 0.78
Epidemiology of CKD Regression in Patients under Nephrology Care. PLoS One (2015) 0.77
Rare cystic liver lesions: a diagnostic and managing challenge. World J Gastroenterol (2013) 0.77
Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr Hypertens Rev (2013) 0.76
Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2012) 0.76
Murine Models of Polycystic Kidney Disease. Drug Discov Today Dis Mech (2013) 0.76
Novel therapeutic approaches to autosomal dominant polycystic kidney disease. Transl Res (2014) 0.76
Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease. Hepatology (2016) 0.76
Medical therapy for polycystic liver disease. Ann R Coll Surg Engl (2016) 0.75
Night blindness in a haemodialysed ADPKD patient receiving octreotide. Clin Kidney J (2012) 0.75
Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes. Eur J Hum Genet (2016) 0.75
Polycystic liver disease. BMJ Case Rep (2014) 0.75
Heterotrimeric G protein signaling in polycystic kidney disease. Physiol Genomics (2016) 0.75
ALADIN: wish granted in inherited polycystic kidney disease? Lancet (2013) 0.75
Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial. Trials (2015) 0.75
Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes. World J Gastroenterol (2016) 0.75
Autopsy report with clinical and pathophysiologic discussion of autosomal dominant adult polycystic kidney disease. Case Rep Urol (2014) 0.75
Patients, cells, and organelles: the intersection of science and serendipity. Hepatology (2011) 0.75
Polycystic kidney disease: Promising new potential therapies for patients with autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2010) 0.75
Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus. Can J Kidney Health Dis (2017) 0.75
Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. Pituitary (2012) 0.75
Polycystic Liver Disease: The Benefits of Targeting cAMP. Clin Gastroenterol Hepatol (2016) 0.75
Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS One (2017) 0.75
TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases via cAMP/Gαs signaling. Hepatology (2017) 0.75
Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease. Case Rep Nephrol Dial (2017) 0.75
Nephronophthisis: should we target cysts or fibrosis? Pediatr Nephrol (2015) 0.75
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med (2003) 3.78
Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int (2009) 3.66
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med (2004) 3.09
Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int (2009) 2.99
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol (2005) 2.92
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med (1990) 1.93
Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet (1999) 1.80
Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet (2003) 1.77
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging (2003) 1.66
The benefit of stereology for quantitative radiology. Br J Radiol (2000) 1.49
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet (2003) 1.47
Antitumor effects of somatostatin. Mol Cell Endocrinol (2008) 1.30
Effects of long term octreotide on gall stone formation and gall bladder function. BMJ (1992) 1.27
Somatostatin analogues reduce liver volume in polycystic liver disease. Gut (2008) 1.25
Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. Am J Hum Genet (2000) 1.24
Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int (2003) 1.23
Hepatic cysts in autosomal dominant polycystic kidney disease. Mayo Clin Proc (1990) 1.10
Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris (2001) 1.08
New software toolkits for comprehensive visualization and analysis of three-dimensional multimodal biomedical images. J Digit Imaging (1997) 1.00
Selective, concurrent bilateral nephrectomies at renal transplantation for autosomal dominant polycystic kidney disease. J Urol (2007) 0.99
Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) (1998) 0.97
Isolation and characterization of rat cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. Biochemistry (1995) 0.95
Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am J Physiol Cell Physiol (2003) 0.93
Hair loss in three patients with acromegaly treated with octreotide. Br J Dermatol (2003) 0.89
Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells. FEBS Lett (1986) 0.87
Use of somatostatin analogues in obesity. Drugs (2008) 0.86
Octreotide-induced bradycardia. Pharmacotherapy (1998) 0.86
Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats. Miner Electrolyte Metab (1982) 0.84
Development of a nonisotopic capillary electrophoresis-based method for measuring glomerular filtration rate. Electrophoresis (1997) 0.83
MEK inhibits secretin release and pancreatic secretion: roles of secretin-releasing peptide and somatostatin. Am J Physiol Gastrointest Liver Physiol (2001) 0.83
Effect of somatostatin on renal water handling in the dog. Can J Physiol Pharmacol (1982) 0.82
Octreotide decreases biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjects. Intern Med (1994) 0.82
Somatostatin: an endogenous peptide in the toad urinary bladder inhibits vasopressin-stimulated water flow. Proc Natl Acad Sci U S A (1980) 0.82
Scalp hair loss caused by octreotide in a patient with acromegaly: a case report. Endocr J (1995) 0.82
Octreotide and loss of scalp hair. Ann Intern Med (1991) 0.81
Octreotide-induced bradycardia and heart block during surgical resection of a carcinoid tumor. Anesth Analg (2004) 0.81
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Progress and prospects in rat genetics: a community view. Nat Genet (2008) 6.01
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Polycystic kidney disease. Annu Rev Med (2009) 4.78
Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol (2004) 4.62
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57
The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet (2002) 4.54
The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol (2008) 4.10
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med (2003) 3.78
Strategies for improving attendance at medical grand rounds at an academic medical center. Mayo Clin Proc (2003) 3.71
Drug-eluting coronary-artery stents. N Engl J Med (2013) 3.69
Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol (2011) 3.66
Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int (2009) 3.66
Incidental findings in imaging research: evaluating incidence, benefit, and burden. Arch Intern Med (2010) 3.40
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
Cryptosporidiosis. N Engl J Med (2002) 3.24
Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience. Catheter Cardiovasc Interv (2005) 3.20
The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat Genet (2006) 3.19
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med (2004) 3.09
Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int (2009) 2.99
Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol (2006) 2.95
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol (2005) 2.92
A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem (2007) 2.89
Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol (2007) 2.88
Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation (2003) 2.81
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol (2007) 2.71
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg (2002) 2.68
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Transcatheter aortic valve implantation: assessing the learning curve. JACC Cardiovasc Interv (2011) 2.63
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol (2010) 2.60
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Myocardial bridging. Eur Heart J (2005) 2.56
Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet (2003) 2.55
Trends in cause of death after percutaneous coronary intervention. Circulation (2014) 2.52
Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol (2003) 2.52
Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol (2005) 2.51
Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv (2010) 2.51
Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int (2010) 2.51
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation (2007) 2.47
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol (2012) 2.44
Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology (2006) 2.43
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2008) 2.42
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol (2009) 2.37
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) (2006) 2.34
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol (2011) 2.33
Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA (2004) 2.32
Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation (2007) 2.31
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.30
Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation (2006) 2.29
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Shock wave lithotripsy and diabetes mellitus: a population-based cohort study. Urology (2011) 2.26
Chronic total occlusion angioplasty in the United States. JACC Cardiovasc Interv (2009) 2.24
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.22
Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: a long-term follow-up study. J Am Coll Cardiol (2005) 2.21